Toronto, Ontario –October 30, 2017
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a leading biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that its latest research will be presented at the 2018 International Society for Optical Engineering (“SPIE”) Photonics West to be held in San Francisco, California from January 27th to February 1st, 2018.
SPIE Photonics West is the world’s largest photonics technologies event, consisting of three conferences and two world-class exhibitions. Every year over 20,000 participants attend to learn more about the latest research and technology in: translational biophotonics, global healthcare, understanding the brain, new lasers for manufacturing, applications of 3D technologies, photonics-based consumer products and other related subject matters.
The “Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XXVII” chairing committee have accepted “Targeting Non-Small Cell Lung Cancer by Novel TLD-1433-Mediated Photodynamic Therapy,” for oral presentation on January 27, 2018.
The “Therapeutics and Diagnostics in Urology” chairing committee has accepted, “Monitoring Irradiance During Full Bladder Irradiation for Ru(II) Photosensitizer Mediated Photodynamic Therapy in NMIBC,” for oral presentation on January 28, 2018.
Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase stated that, “The Company has previously reported that in the Phase Ib clinical study of Non-Muscle Invasive Bladder Cancer (“NMIBC”) that the first 3 patients treated at the Maximum Recommended Starting Dose (“MRSD”) were visibly free of tumours at 3 months post treatment. Theralase will now present to the scientific and medical community, the results that have shown the ability of TLD-1433-based PDT to destroy Non-Small Cell Lung Cancer (“NSCLC”) in various pre-clinical models. This latest peer-reviewed research supports the Company’s clinical mandate to advance the PDT technology platform across multiple oncological targets.”
Roger Dumoulin-White, President and CEO of Theralase stated that, “This latest peer-reviewed research confirms that the Company is on the right track to provide support for the design and commencement of additional Phase Ib clinical studies, utilizing the Company’s cutting-edge PDT technology, for patients inflicted with various forms of this deadly disease.”